Provectus Revenue and Competitors

Location

N/A

Total Funding

Analytics

Industry

Estimated Revenue & Valuation

  • Provectus's estimated annual revenue is currently $84.9M per year.(i)
  • Provectus's estimated revenue per employee is $175,000

Employee Data

  • Provectus has 485 Employees.(i)
  • Provectus grew their employee count by -12% last year.

Provectus's People

NameTitleEmail/Phone
1
Co-founder, CTO/CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Senior Solution OwnerReveal Email/Phone
4
Senior Solution OwnerReveal Email/Phone
5
Head MarketingReveal Email/Phone
6
Head Alliances and Business DevelopmentReveal Email/Phone
7
Founder and Board DirectorReveal Email/Phone
8
Director, Managed ServicesReveal Email/Phone
9
Director People and CultureReveal Email/Phone
10
Delivery Director, Data / ML / CloudReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.5M18N/AN/AN/A
#2
$0.6M90%N/AN/A
#3
$13.6M973%N/AN/A
#4
$82.3M4630%$6.8MN/A
#5
$11.6M83-3%N/AN/A
#6
$56.2M316-15%$131.5MN/A
#7
$0.6M9-47%N/AN/A
#8
$0.3M40%N/AN/A
#9
$0.8M10N/AN/AN/A
#10
$2.8M29N/AN/AN/A
Add Company

What Is Provectus?

Provectus is an Artificial Intelligence consultancy and solutions provider, helping businesses achieve their objectives through AI. We are recognized by industry think tanks as a leading provider of AI solutions in specific business domains, driven by sophisticated IT service management and tech innovation. Provectus is a value driver and a trusted partner for our clients and employees. Provectus is an AWS Premier Consulting Partner with competencies in Data & Analytics, DevOps, and Machine Learning. We design and build AI solutions for industry-specific use cases, Data and Machine Learning foundation, Cloud transformation, and DevOps adoption.

keywords:N/A

N/A

Total Funding

485

Number of Employees

$84.9M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Provectus News

2022-04-19 - Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical...

2022-04-17 - PROVECTUS BIOPHARMACEUTICALS ANNOUNCES NOTICE OF ALLOWANCE OF FIRST U.S. PATENT APPLICATION FOR USE OF PV-10 IMMUNOTHERAPY IN HEMATOLOGY

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES NOTICE OF ALLOWANCE OF FIRST U.S. PATENT APPLICATION FOR USE OF PV-10 IMMUNOTHERAPY IN HEMATOLOGY.

2022-04-17 - Provectus Biopharmaceuticals Announces Notice of ...

KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$93.2M49420%$0.8M
#2
$129.8M50114%$87.9M
#3
$207.9M50428%N/A
#4
$136M52529%$220M
#5
$96.8M53428%N/A